Reaction
Injection Related Reaction reporting signals
As of the last recalculation, Injection Related Reaction appears in 1,588 FAERS reports alongside 30 co-occurring drug terms. The strongest observed disproportionality signal is OFATUMUMAB (PRR 42.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ofatumumab | 102 | 42.9 | 43.1 |
| Asfotase Alfa | 23 | 30.5 | 30.6 |
| Glatiramer Acetate | 109 | 25.6 | 25.6 |
| Cabotegravir | 15 | 24.6 | 24.6 |
| Fremanezumab-Vfrm | 20 | 23.1 | 23.2 |
| Omalizumab | 72 | 11.6 | 11.6 |
| Inclisiran | 5 | 8.2 | 8.2 |
| Ixekizumab | 22 | 7.9 | 7.9 |
| Ustekinumab | 59 | 7.8 | 7.8 |
| Desoximetasone | 11 | 7.6 | 7.6 |
| Testosterone Cypionate | 5 | 7.4 | 7.4 |
| Guselkumab | 18 | 6.7 | 6.7 |
| Iohexol | 4 | 6.3 | 6.3 |
| Peginterferon Beta-1A | 6 | 6.0 | 6.0 |
| Mepolizumab | 22 | 5.9 | 5.9 |
| Obinutuzumab | 7 | 5.6 | 5.6 |
| Benralizumab | 8 | 5.3 | 5.3 |
| Daratumumab | 15 | 5.0 | 5.0 |
| Golimumab | 31 | 4.8 | 4.8 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 4 | 4.8 | 4.8 |
| Alirocumab | 9 | 4.7 | 4.7 |
| Aflibercept | 11 | 4.6 | 4.6 |
| Galcanezumab-Gnlm | 11 | 4.6 | 4.6 |
| Sarilumab | 9 | 4.5 | 4.5 |
| Apalutamide | 4 | 4.5 | 4.5 |
| Erenumab-Aooe | 17 | 4.1 | 4.1 |
| Onabotulinumtoxina | 21 | 3.6 | 3.6 |
| Abaloparatide | 8 | 3.6 | 3.6 |
| Evolocumab | 26 | 2.1 | 2.1 |
| Tirzepatide | 17 | 1.4 | 1.4 |